Lapatinib or trastuzumab? Which anti-HER2 treatment is more effective in the treatment of patients with HER2-positive breast cancer with brain metastases? An Anatolian Society of Medical Oncology Study

Kaplan, Muhammet AliIsikdogan, AbdurrahmanKoca, DoganKucukoner, MehmetGumusay, OzgeYildiz, RamazanOztop, Ilhan2024-08-042024-08-0420120732-183X1527-7755https://hdl.handle.net/11616/10356748th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 01-06, 2012 -- Chicago, IL[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]Lapatinib or trastuzumab? Which anti-HER2 treatment is more effective in the treatment of patients with HER2-positive breast cancer with brain metastases? An Anatolian Society of Medical Oncology StudyConference Object3015WOS:000318009800398Q1